On September 5, 2024, the overseas holding company Pheton Holdings Ltd (referred to as Feitian Zhaoye) of Beijing Feitian Zhaoye Technology Co., Ltd., a cancer radiotherapy planning system supplier from Peking, successfully listed on nasdaq in the USA with the stock code PTHL. It had submitted confidential documents to the SEC in the USA on June 2, 2023, and subsequently publicly disclosed its prospectus on October 11, 2023.

Feitian Zhaoye plans to issue 2.25 million common shares at $4 per share, raising $9 million.

Feitian Zhaoye Prospectus Link:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1970544/000121390024053646/ea0202636-03.htm

Feitian Zhaoye, as a medical care solutions provider, is dedicated to the development and commercialization of a close-range radiotherapy treatment planning system (TPS) specially designed for radioactive particle implantation. This is a form of radiotherapy that kills cancer cells, shrinks tumors, and treats cancer patients by placing radiation sources inside the patient's body.